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Ovarian small cell carcinoma is a rare and highly malignant neoplasm carrying a poor prognosis. Although combination
chemotherapy remains the cornerstone of treatment due to the rarity of these tumors, no regimen can be recommended as
standard of care although in the majority of cases platinum-based regimens are used. Herein, we report two cases of small cell
carcinoma of the ovaries along with a review of the relevant literature.
1.Introduction
Ovarian small cell carcinoma is a rare and highly malignant
neoplasm that typically occurs in young females. It is
generally unilateral. Patients often present with abdominal
discomfort, and two thirds of the cases are associated
with hypercalcemia. Because of the rareness of this disease,
there are no evidence-based treatment recommendations
(Table 1). Herein, we report two cases of ovarian small
cell carcinoma. We also discuss the existing bibliography
regarding its clinical presentation and treatment.
2.CaseReports
Case 1. The ﬁrst patient, aged 16, presented with a 2-week
abdominal pain. Computed tomographic (CT) scan of the
abdomen and pelvis revealed the presence of a complex
adnexal mass (10 × 11 × 14.5cm), seemingly arising
from the left ovary while peritoneal ﬂuid was also present.
The laboratory tests performed were within normal range
except elevated serum levels of LDH. No hypercalcemia was
noted. Preoperatively, the serum Ca125 level was 172U/mL.
There was no radiographic evidence of distant metastases.
A biopsy was performed, indicative of a stromal neoplasm
and particularly a granulosa cell tumor. Due to the rapidly
growing tumor, the patient developed obstructive anuria,
necessitating the placement of a pig-tail-catheter.
She underwent exploratory laparotomy with suboptimal
tumor excision including total abdominal hysterectomy,
bilateral salpingo-oophorectomy, omentectomy, excision of
part of the ileum, and the inﬁltrated sigmoid colon. The
tumor was located on the surface of the right ovary, inﬁ-
ltrated the fat of the small intestine, the muscle tissue of the
colon, the exterior surface of the uterus, and the connective
to left ovary tissue. Perceptive residual disease remained in
Douglas area and in enlarged para-aortic lymph nodes. The
resected left ovarian mass measured grossly 17.5cm and had
a tan-white, lobulated external surface, and solid and cystic
areas with focal necrosis. Microscopically, the tumor showed
closely packed, small but mostly large cells, with abundant
cytoplasm, prominent nucleoli, and little cell diﬀerentiation.
Extended areas of necrosis were present and mitotic ﬁgures
were frequent (more than 20 mitoses/10HPF). Immunohis-
tochemical stains showed strong staining of tumor cells with
antibodies to WT1, weak focal staining to Pan CK, CK7,
EMA, vimentin, calretin, and CD99. Those characteristics
set the diagnosis of small cell ovarian cancer, the large cell
variant.2 Case Reports in Medicine
Table 1: Literature review of the treatment of small cell carcinoma of the ovaries.
Trial n Regimen
Young et al. [1] 150 Vincristine, vinblastine, cyclophosphamide,doxorubicin, etoposide, and cisplatin.
Chen et al. [2] 1 Paclitaxel/carboplatin followed by consolidationpaclitaxel.
Tewari et al. [3] 1 Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide.
Benrubi et al. [4] 1 Cyclophosphamide, doxorubicin, cisplatin, vincristine, and etoposide.
Rana et al. [5] 1 Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide.
Distelmaier et al. [6]1 1
Cisplatin, etoposide, ifosfamide (n = 4pts) carboplatin, etoposide, vincristine, actinomycin,
ifosfamide, and adriamycin (n = 2pts) carboplatin/paclitaxel followed by
cyclophosphamide/paclitaxel (n = 1pts).
Dykgraaf et al. [7] 1 Bleomycin, etoposide, and cisplatin.
McCormick et al. [8] 1 Cisplatin and etoposide.
Nelsen et al. [9]1 Two cycles of intensive cyclophosphamide, etoposide, and cisplatin regimen, followed by three cycles
of ifosfamide, carboplatin and etoposide and an autologous peripheral blood stem cell transplant.
The patient was diagnosed with stage IIIC disease and
was referred for chemotherapy. She received 3 cycles of
chemotherapy with BEP (bleomycin, etoposide, cisplatin),
with relatively good tolerance, beside hematologic toxicity
(afebrile gr IV neutropenia, gr I anemia). Due to local
disease progression, the regimen was altered to irinotecan
and liposomal doxorubicin. She received one cycle with no
response. She developed bowel obstruction and despite pal-
liative radiotherapy (2000cGy with abdominal bath, 150cGy
per day, ﬁve days a week), to which she showed some early
clinical response, clear progressive disease could be docu-
mented. She died six months after the initial diagnosis.
Case 2. The secondpatient,aged19,presentedwith a4-week
abdominal pain and constipation, before her admittance
with bowel obstruction. A palpable mass was prominent in
the lower abdomen and radiographic tests (chest, abdomen
and pelvis CT scan) revealed a mass in the lower pelvis
obstructing the ureters bilaterally, causing distal distention,
probably inﬁltrated the rectum and dislocated the uterus.
Colonoscopy showed mucosal ulcers and pressure from the
outside on the rectosigmoid area. Laboratory tests, including
serum calcium measurement, were also within normal levels
except elevated serum levels of LDH. Preoperatively, Ca125
was 71.4U/mL. She underwent exploratory laparotomy
that revealed free peritoneal ﬂuid and a right ovarian
mass inﬁltrating the colon. Suboptimal mass excision, total
abdominal hysterectomy, bilateral salpingo-oophorectomy,
omentectomy, and appendectomy were performed; in addi-
tion, low anterior resection and colostomy were performed.
Postsurgically, perceptible evidence of disease remained
locally and in the left parametrium area.
Gross examination showed a large (14 × 13 × 10.5cm),
solid, pale brown mass, inﬁltrating the omentum, the
outer surface of the uterus, and part of the sigmoid.
Microscopic examination showed medium sized cells, with
round nuclei, prominent nucleoli, and eosinophilic cyto-
plasm while some contained intracytoplasmic eosinophilic
globules. Tumor cells mostly grew in a diﬀuse pattern.
There was brisk mitotic activity (>17 mitoses/10HPF) and
foci of necrosis. Occasional follicle-like spaces containing
eosinophilic material were present. Vascular invasion and
surface involvement was noted. Immunochemical studies
revealed the tumor cells were immunoreactive for vimentin
and focally immunoreactive for EMA, and pan-cytokeratin.
Furthermore, immunoreactivity for p53 was documented in
more than 70% of the tumor cells. The diagnosis was small
cell tumor of the ovary.
The patient was referred for chemotherapy and, initially,
received 2 cycles of BEP, with moderate tolerance (episode
of gr IV neutropenia that demanded the prophylactic use
of GCSF, gr II anemia that responded well to rh-EPO, gr
IV thrombocytopenia). The patient achieved stable disease
as her best response, on the basis of CT scans, but due to
clinical beneﬁt and decrease of the Ca125 serum levels, 3
more cyclesofetoposide/cisplatindoubletwereadministered
(bleomycin was removed from the regimen due to poor
tolerance). Three weeks after the end of chemotherapy,
the patient developed bowel obstruction and symptomatic
hypercalcemia which was treated with zolendronic acid. CT
scans revealed disease progression in the liver with new
lesions and local recurrence in the lower abdomen. Second-
line chemotherapy with irinotecan and liposomal doxorub-
icin was administered twice, before the patient developed
rectal hemorrhage because of local inﬁltration and palliative
radiotherapy was initiated. The patient died 7 months after
the initial diagnosis.
3.Background
Small cell carcinoma of the ovary (hypercalcemic type, SCC-
HT) is a rare and highly malignant tumor. It generally occurs
in young women between 10 and 40 years of age (mean
age, 23 years) [1]. Less than 30% of tumors develop in
patients youngerthan 20 years and <1% developin children.
The youngest patient reported to date has been 14 months
[1, 10]. It is usually unilateral (99%), but bilateral familial
cases have been reported [11]. Since its ﬁrst description
in 1982 by Dickersin and colleagues [12], approximately
190 patients have been reported with OSCCHT—the largest
series reported to date included 150 patients [1]. Approx-
imately, 66% of cases are associated with paraneoplasticCase Reports in Medicine 3
hypercalcaemia in the genesis of which the secretion by the
tumour cells of parathyroid hormone-related protein has
been suggested [1, 2, 13]. This phenomenon also provides
a convenient biochemical marker, useful for followup.
The diﬀerential diagnosis is broad and includes adult
and juvenile granulosa cell tumor, primitive germcell tumor,
malignant lymphoma, primitive neuroectodermal tumor,
neuroblastoma, desmoplastic small round cell tumor, small
cell carcinoma (pulmonary type), and metastatic small cell
carcinoma.
The most common microscopic pattern is a sheet-like
arrangement of small, closely packed epithelial cells. A
helpful, but often very focal, ﬁnding in 80% of cases is
variably sized follicles that contain eosinophilic ﬂuid or are
empty. The most common diﬀerence from this pattern,
present in about half the tumors, is a component of large
cells that usually represents a minor to moderate component
of the tumor, but rarely can be the predominant or even
exclusive component, leading to use of the descriptor “large
cell variant” [1], the variant observed in our ﬁrst patient.
The histogenesis of small cell carcinoma of ovary is
unknown. The tumor cells cannot be subtyped as surface
epithelial, germ cell, sex-cord, or neuroendocrine cells. In
terms of oncogenesis, approximately 80% of small cell car-
cinomas of ovary overexpress p53 protein, as seen in our
second patient, suggesting that a p53 mutation may be an
underlying cause [14]. Similar to other malignancies, in
ovarian small cell carcinoma, overexpression of p53 may
not explain entirely the origin of tumorigenesis, and further
investigation is needed.
4.Discussion
Ovarian small cell tumors are highly aggressive tumors. At
least half of them have spread beyond the ovary at the time
of laparotomy, but this may be an underestimation as many
of the patients were not optimally staged [1]. Metastatic
tumors occur mostly within the pelvis and abdomen, but
hematogenous spread also occurs. The primary therapy of
this tumor is unilateral salpingo-oophorectomy in stage IA,
that has a reported postoperative disease-free survival rate
of approximately 33% throughout 1 to 13 years. However,
even at stage IA, more than 50% of patients die of their
disease. Almost all patients with higher stage tumors die of
disease, usually within 2years. Eﬀectivetreatment ofpatients
with high-stage tumors or recurrent disease has not yet
beenachieved,althoughrarepatientswithhigh-stagetumors
have survived over 4 years after intensive chemotherapy,
radiation therapy, or both [1, 3, 4]. Potentially favorable
prognostic features in stage IA cases include: age > 30
years, normal preoperative calcium level, tumor size up to
10cm,absenceoflargecells,operationthatincludedbilateral
oophorectomy, and postoperative radiation therapy [1]. In
the largest published series on OSCCHT, the majority of
150 patients received some form of adjuvant chemotherapy.
However, only 7 patients showed a favorable response to
therapy, which in their case, consisted of various regimens,
including anthracyclins, etoposide, cisplatin, and alkylating
agents [1]. Young et al. [1] proposed a more radical surgi-
cal therapy, including hysterectomy and bilateral salpingo-
oophorectomy. However, more recent reports have indicated
that a fertility sparing surgical approach, in conjugation with
multiagent adjuvant chemotherapy, may not compromise
the survival of these patients [5, 6, 15]. In a report by
Harrison et al. [15], 17 patients received adjuvant cisplatin-
and etoposide-based chemotherapy. In total, 6 of 10 patients
with Stage I disease and 1 of 7 patients with Stage III disease
werealiveanddisease-free atthetimeofthereport.Similarly,
tworecentpapersbyDykgraafetal.[7]andM cCormicketal.
[8] reported two cases of patients who were operated and
subsequently received platinum-based therapy (bleomycin,
etoposide, and cisplatin in the Dykgraaf et al. paper [7]
and cisplatin-etoposide in the McCormick et al. paper [8]).
Dykgraaf et al. reported a substantial relapse-free survival
of 60 months [7]. Another recently published paper by
Nelsen et al. [9] reported a case of 25-year old female
who was operated for a IIIC small cell carcinoma of the
ovary. After surgery, the patient received two cycles of inten-
sive cyclophosphamide, etoposide, and cisplatin regimen,
followed by three cycles of ifosphamide, carboplatin, and
etoposide and an autologous peripheral blood stem cell
transplant. The patient was free of recurrence, 17 months
after her initial diagnosis.
It is worth noting that paclitaxel-based regimens, com-
monly used in other types of ovarian cancer, demonstrated
only limited eﬃcacy in both ﬁrst line and salvage therapy
[6, 15]. Harrison et al. [15] also concluded that radiother-
apy had a signiﬁcant additional therapeutic impact, while
Baeyensetal.reported theﬁrst casethathasbeensuccessfully
cured by surgery plus adjuvant radiotherapy only [16].
In summary, the optimal management of OSCCHT re-
mains unknown. Currently, a platin-based regimen that in-
cludes etoposide, alkylating agents, and anthracyclines ap-
pears to be the most promising and requires further evalu-
ation.
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